Decrease in viral load at weeks 12 and 24 in patients with chronic hepatitis B treated with lamivudine or adefovir predicts virological response at week 48.

Llop, E; de la Revilla, J; Pons, F; Peñas, B; Martínez, J L; Abreu, L; Calleja, J L

Llop, E; de la Revilla, J; Pons, F; Peñas, B; Martínez, J L; Abreu, L; Calleja, J L.

Affiliation

Llop E; Service of Gastroenterology and Hepatology, University Hospital Puerta de Hierro, Madrid, Spain.

Rev Esp Enferm Dig ; 101(11): 763-7, 2009 Nov.

Article in En | MEDLINE | ID: mdl-20001153

Subject(s)

Adenine/analogs & derivatives; Antiviral Agents/therapeutic use; Hepatitis B, Chronic/drug therapy; Hepatitis B, Chronic/virology; Lamivudine/therapeutic use; Organophosphonates/therapeutic use; Reverse Transcriptase Inhibitors/therapeutic use; Viral Load/drug effects; Adenine/pharmacology; Adenine/therapeutic use; Adult; Antiviral Agents/pharmacology; Female; Forecasting; Humans; Lamivudine/pharmacology; Male; Organophosphonates/pharmacology; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors/pharmacology; Time Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Adenine / Reverse Transcriptase Inhibitors / Lamivudine / Viral Load / Hepatitis B, Chronic / Organophosphonates Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Journal: Rev Esp Enferm Dig Journal subject: GASTROENTEROLOGIA Year: 2009 Type: Article Affiliation country: Spain

Search on Google

XML

PubMed Links